Endpoints NewsOriginal article
AstraZeneca does AI deal with insitro; inVIOs' Phase 1 success in solid tumors
PartnershipPositive
AI Analysis
Summary
AstraZeneca entered into an AI drug discovery partnership with insitro, paying $40 million upfront. inVIO reported Phase 1 success in solid tumors.
Clinical Trial Data
Phase
Phase_1
Primary Endpoint
Met
Outcome Details
$40 million upfront payment from AstraZeneca to insitro for AI drug discovery collaboration
Importance:6/10
Sentiment:
0.60
AI_drug_discoverypartnershipPhase_1_datasolid_tumors
Related Companies
Read the original article
Published by Endpoints News on October 15, 2026 3:30 PM